Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    LUT-014

    DEVELOPMENTS

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Lut014, 2274819-46-2, Lut-014, T4e4i523ry, Lut-014 [who-dd], 6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]-1-n-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine
    Molecular Formula
    C27H19F3N8O
    Molecular Weight
    528.5  g/mol
    InChI Key
    FZPYULHBUBXPIG-UHFFFAOYSA-N
    FDA UNII
    T4E4I523RY
    BRAF Inhibitor LUT014 is a topically bioavailable small molecule inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential chemoprotective activity. Upon topical administration, BRAF inhibitor LUT014 targets and binds BRAF and, through the paradoxical effect of BRAF inhibition, induces mitogen-activated protein kinase (MAPK) signaling, which leads to the proliferation and migration of healthy human keratinocytes. This decreases dermal toxicities associated with epidermal growth factor (EGFR) inhibitor therapy. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of MAPK/extracellular signal-regulated kinase (ERK) signaling pathways.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    6-methyl-5-N-[3-(7H-purin-6-yl)pyridin-2-yl]-1-N-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine
    2.1.2 InChI
    InChI=1S/C27H19F3N8O/c1-15-7-8-19-18(9-11-32-24(19)37-16-4-2-5-17(12-16)39-27(28,29)30)21(15)38-25-20(6-3-10-31-25)22-23-26(35-13-33-22)36-14-34-23/h2-14H,1H3,(H,31,38)(H,32,37)(H,33,34,35,36)
    2.1.3 InChI Key
    FZPYULHBUBXPIG-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C2=C(C=C1)C(=NC=C2)NC3=CC(=CC=C3)OC(F)(F)F)NC4=C(C=CC=N4)C5=C6C(=NC=N5)N=CN6
    2.2 Other Identifiers
    2.2.1 UNII
    T4E4I523RY
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 6-methyl-5-n-(3-(7h-purin-6-yl)pyridin-2-yl)-1-n-(3-(trifluoromethoxy)phenyl)isoquinoline-1,5-diamine

    2. Lut014

    2.3.2 Depositor-Supplied Synonyms

    1. Lut014

    2. 2274819-46-2

    3. Lut-014

    4. T4e4i523ry

    5. Lut-014 [who-dd]

    6. 6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]-1-n-[3-(trifluoromethoxy)phenyl]isoquinoline-1,5-diamine

    7. 1,5-isoquinolinediamine, 6-methyl-n5-(3-(9h-purin-6-yl)-2-pyridinyl)-n1-(3-(trifluoromethoxy)phenyl)-

    8. 1,5-isoquinolinediamine, 6-methyl-n5-[3-(9h-purin-6-yl)-2-pyridinyl]-n1-[3-(trifluoromethoxy)phenyl]-

    9. Unii-t4e4i523ry

    10. Schembl22356326

    11. Gtpl11568

    12. Ex-a2985

    13. Zqd81946

    14. Mfcd32062738

    15. Zb1544

    16. Ac-35618

    17. Hy-111940

    18. Cs-0094163

    19. D81245

    20. N5-(3-(9h-purin-6-yl)pyridin-2-yl)-6-methyl-n1-(3-(trifluoromethoxy)phenyl)isoquinoline-1,5-diamine

    2.4 Create Date
    2019-05-15
    3 Chemical and Physical Properties
    Molecular Weight 528.5 g/mol
    Molecular Formula C27H19F3N8O
    XLogP36.2
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count11
    Rotatable Bond Count6
    Exact Mass528.16339175 g/mol
    Monoisotopic Mass528.16339175 g/mol
    Topological Polar Surface Area114 Ų
    Heavy Atom Count39
    Formal Charge0
    Complexity808
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)